Dupuytren's Disease Evaluation of Preventative or Adjuvant Radiation Therapy: DEPART
Yale University
Summary
This is a randomized study to determine whether radiation therapy reduces the risk of progression / recurrence of Dupuytren's disease / contracture.
Eligibility
- Age range
- 30+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * English-speaking * Patient consent * No previous radiotherapy to the affected hand * No history of radiation sensitivity diseases (e.g. Scleroderma, Ataxia Telangiectasia, Li Fraumeni) * Age\>30 * Life expectancy \>5 years * Available and willing to participate in at least 5 years of follow-up * Female patients capable of child-bearing that are not pregnant Exclusion Criteria: * Pregnancy or lactation * Known genetic disease that would make them extremely sensitive to radiation therapy, e.g. Scleroderma, Ataxia Telangiectasia, Li Fraumeni
Interventions
- RadiationRadiation Therapy
Radiation therapy (RT) should commence within 12 weeks of randomization in the prevention group and within 12 weeks of local treatment (NA) for the adjuvant group. RT will consist of 30Gy in 10 equal fractions. The RT schedule will be 5 initial fractions, then a 4-12 week break and then the final 5 fractions. Each group of 5 treatments must be delivered within a 7 day period.
Location
- Greenwich HospitalGreenwich, Connecticut